Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Collagen Solutions rises as it launches new online store

The online store will sell standard collagen products directly to end users in the research market
collagen
Collagen Solutions manufactures and supplies collagen for use in regenerative medicine and other medical research

Shares in Collagen Solutions PLC (LON:COS) edged higher on Monday morning after the medical grade collagen manufacturer launched a new business-to-consumer (B2C) web-based business in the US.

The online store will sell standard collagen products directly to end users in the research market.

The Minneapolis-headquartered group called the online offering an “important initiative” as it directly connects COS with its end users and allows it to better understand and address the purchasing needs of researchers.

The company told investors that, in the longer-term, that should help it to make sure it’s supplying the right products to the right markets, the company told investors.

“This initiative serves three purposes for Collagen Solutions,” said chief executive Jamal Rushdy.

“First, it increases our access to the estimated US$200m global market for cell culture reagents.

“Secondly, it gives us a direct link with the end users of our products so that we can understand their needs and how the market for collagen is evolving.

“Finally, it establishes Collagen Solutions as the go-to collagen supplier among investigators.”

Shares gained 5% to 5.14p on Monday morning.

View full COS profile View Profile

Collagen Solutions PLC Timeline

Related Articles

brokerreport.jpg
January 25 2017
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
Bankroll.jpg
March 01 2017
The new funds will be used to expand the pre-clinical and early-clinical development of the company’s immuno-oncology drug, Clevegen

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use